1-4 of 4
Lincy S. Lal, PhD
Close
Sort by
Journal Articles

The First Retrospective Commercial Claims-Based Analysis of CAR T Treated Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Anna Purdum, PharmD,MS, Jonathan Johnson, Anthony Bonagura, Liliosa Nyamutswa, MPH, Caitlin Elliott, MS, Lincy S. Lal, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31.
https://doi.org/10.1182/blood-2020-134735
Published: 2020
Journal Articles

Evaluation of Treatment Outcomes after Second-Line Treatment Among Adult Patients with Immune Thrombocytopenia

Qayyim Said, PhD, Lincy S Lal, PhD, Brigette Nezami, PharmD, Katherine Andrade, J. Anthony Graves, MD, PhD, Anuja Roy, PhD, Adam Cuker, MD MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 3765.
https://doi.org/10.1182/blood-2018-99-115197
Published: 2018
Journal Articles

Bleeding Related Episodes, Thrombotic Events and Platelet Counts Among Immune Thrombocytopenia Patients Receiving Second Line Therapy

Qayyim Said, PhD, Lincy S Lal, PhD, Katherine Andrade, Brigette Nezami, PharmD, J. Anthony Graves, MD, PhD, Anuja Roy, PhD, Adam Cuker, MD MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 2436.
https://doi.org/10.1182/blood-2018-99-111975
Published: 2018
Journal Articles

Impact of Safety Concerns of Erythropoiesis-Stimulating Agents (ESAs) and Regulatory Changes on the Use of ESAs and Red Blood Cell (RBC) Transfusions at a Comprehensive Cancer Center

Saroj Vadhan-Raj, UTMD, Victoria E. Hawkins, MPH, DRPH, RN, Xiao Zhou, MD, PHD, Kurt Sizer, MD, Lincy S. Lal, PHD, PHARMD, RPH, Joyce Roquemore, MBA, CPHQ, Rebecca B. Arbuckle, MS, RPH, Robert S. Benjamin, MD, BA, Benjamin Lichtiger, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1300.
https://doi.org/10.1182/blood.V112.11.1300.1300
Published: 2008